Dr. Brian Koffman recently had the opportunity to participate in a webinar for media, Verastem Oncology and PI3K Inhibition: A Backgrounding Session, alongside his esteemed colleague and friend, John Pagel M.D., Ph.D., Chief of Hematologic Malignancies, Director of Hematopoietic Stem Cell Transplantation Program, Swedish Cancer Institute, and Verastem leadership, Dan Paterson, President and COO, and Jonathan Pachter, Ph.D., Chief Scientific Officer. Hosted by Verastem Oncology, the virtual session was intended to provide medical writers who are preparing for the American Society of Hematology (ASH) Annual Meeting with background on CLL/SLL, the patient experience and the treatment landscape, including PI3K inhibition.
Dr. Koffman had the opportunity to share his personal journey with CLL, as well as the below important key takeaways for patients living with CLL and their families:
- Build your team and include a CLL expert to help understand options/choices along the way.
- Like a chess game, think about more than just the next move as patients are living longer with CLL/SLL and may have multiple therapies.
- Find the right support and advice for yourself, be part of the decision-making process and be accepting of uncertainty.